Table 2.

Results from the statistical analysis of differences in apolipoproteins levels in CSF and plasma samples, between PD patients and matched controls from the Stockholm cohort

			Kruskal−Wallis
Analyzed apolipoprotein	Mann−Whitney		CSF			Plasma
	CSF Control vs. PD	Plasma Control vs. PD	Control vs. PD treated	PD treated vs. PD untreated	Control vs. PD untreated	Control vs. PD treated	PD treated vs. PD untreated	Control vs. PD untreated
ApoAI	0.7995	0.0048	>0.9999	>0.9999	>0.9999	0.0598	>0.9999	0.0697
ApoCI	0.4245	0.6176	0.0807	0.0439	>0.9999	>0.9999	0.1918	0.5398
ApoE	<0.0001	0.8194	0.0023	0.2830	<0.0001	0.7492	0.4278	>0.9999
ApoJ	0.0116	0.639	0.0413	>0.9999	0.2601	>0.9999	0.4312	0.7826

The left part of the table represents P values obtained after analyzing apolipoproteins’ levels in PD (PD) patient set vs. healthy controls (the Mann−Whitney U test). The right part of the table represents P values obtained after splitting the PD group into treated and untreated patients’ subsets and analyzing apolipoproteins’ levels between them and vs. healthy controls (the Kruskal−Wallis H test with a Dunn’s correction). P values < 0.05 are considered significant and are marked with a bold font.